Single nucleotide polymorphisms (SNPs) and circulating endothelial cells (CECs) as outcome predictors in recurrent glioblastoma (rGBM) patients (pts) treated with bevacizumab (BEV) and sorafenib (SOR). Anderson, S. K. , Lafky, J. M. , Carrero, X. W. , Kimlinger, T. K. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0776
Validating RNAseq-Signatures of Vorinostat (VOR) Sensitivity and Resistance in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with VOR, Temozolomide and Radiation Therapy From Alliance N0874/ABTC-0902. Anderson, S. Keith , Miller, C. Ryan , Sarkaria, Jann N. ... - ASCO - J. Clin. Oncol. - 2016 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0874 , ABTC-0902
The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme Ballman, Karla V. , Buckner, Jan C. , Brown, Paul D. ... - - Neuro-oncol - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D
Alliance A071101: A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Bloch, Orin , Shi, Qian , Anderson, S. Keith , Knopp, Michael ... - SNO - Neuro-Oncology - 2017 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - A071101
Development of Clinical Precision Medicine Approaches in Meningiomas: Alliance A071401. Brastianos, Priscilla , Shi, Qian , Santagata, Sandro ... - SNOM - - 2016 Abstract - No-Endpoint Endpoint - Trial-Description-Only Analysis - Neuro-Onc - A071401
Long term outcomes from intergroup NCCTG 86-72-51 (Alliance): Final report of a phase III prospective randomized trial of high dose versus low dose radiation therapy in adults with supratentorial low-grade glioma. Breen, William G. , Anderson, S. Keith , Carrero, Xiomara W ... - SNO - Neuro-Oncology - 2019 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-85-72-51
Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma. Breen, William G , Anderson, S Keith , Carrero, Xiomara W ... - - Neuro-oncology - 2020 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-86-72-51
A phase II trial (N0177) of erlotinib and temozolomide (TMZ) combined with radiation therapy (RT) in glioblastoma multiforme (GBM) Brown, P. D. , Krishnan, S. , Sarkaria, J. , Wu, W. , Mischel, P. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N0177
Adult patients with supratentorial pilocytic astrocytoma: long-term follow-up of prospective multicenter clinical trial NCCTG-867251 (Alliance) Brown, Paul D. , Anderson, S. Keith , Carrero, Xiomara W. ... - - Neurooncol Pract - 2015 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - NCCTG-86-72-51
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases. Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - SNO - Neuro Oncol - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
NCCTG N0574 (Alliance): A Phase III Randomized Trial of Whole Brain Radiation Therapy (WBRT) in Addition to Radiosurgery (SRS) in Patients with 1 to 3 Brain Metastases Brown, Paul D. , Asher, Anthony L. , Ballman, Karla V. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
N107C/CEC.3 (Alliance/NCIC): Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease Brown, Paul D. , Ballman, Karla V. , Cerhan, Jane H. ... - ASTRO - Int. J. Radiat. Oncol. Biol. Phys. - 2016 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Effect of Radiosurgery Alone vs Radiosurgery With Whole Brain Radiation Therapy on Cognitive Function in Patients With 1 to 3 Brain Metastases Brown, Paul D. , Jaeckle, Kurt , Ballman, Karla V. , Farace, Elana ... - - JAMA - 2016 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0574
Phase I/II Trial of Erlotinib and Temozolomide With Radiation Therapy in the Treatment of Newly Diagnosed Glioblastoma Multiforme: North Central Cancer Treatment Group Study N0177 Brown, Paul D. , Krishnan, Sunil , Sarkaria, Jann N. , Wu, Wenting ... - - J Clin Oncol - 2008 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0177
Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC·3): a multicentre, randomised, controlled, phase 3 trial Brown, Paul D , Ballman, Karla V , Cerhan, Jane H , Anderson, S Keith ... - - Lancet Oncol. - 2017 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N107C
Prognosis in patients with anaplastic oligoastrocytoma is associated with histologic grade. Buckner, Jan C , O'Fallon, Judith R , Dinapoli, Robert P ... - - J. Neurooncol. - 2007 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-94-72-52
Stereotactic Radiosurgery with or without Whole Brain Radiotherapy for Limited Brain Metastases: A Secondary Analysis of the NCCTG N0574 (Alliance) Randomized Controlled Trial Churilla, Thomas M. , Ballman, Karla V. , Brown, Paul D. ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2017 Manuscript - Secondary Endpoint - Primary Analysis - Neuro-Onc - N0574
Validation of EORTC Prognostic Factors for Adults with Low-Grade Glioma: a Report Utilizing Intergroup 86-72-511 Daniels, Thomas B. , Brown, Paul D. , Felten, Sara J. , Wu, Wenting ... - - Int J Radiat Oncol Biol Phys - 2011 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - NCCTG-86-72-51
Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma Ellingson, Benjamin M , Abrey, Lauren E , Nelson, Sarah J ... - - Neuro-oncology - 2018 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - N0874
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma multiforme: a north central cancer treatment group study. Friday, B. B. , Buckner, J. , Anderson, S. K. , Giannini, C. ... - SNO - 15th Annual Meeting of the Society for Neuro-Oncology (SNO) - 2010 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0779
Phase II trial of vorinostat in combination with bortezomib in recurrent glioblastoma: a north central cancer treatment group study Friday, Bret B. , Anderson, S. Keith , Buckner, Jan , Yu, Chunrong ... - - Neuro Oncol - 2012 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0779
NCCTG phase II trial of bevacizumab in combination with sorafenib (BEV/SOR) in recurrent glioblastoma (RGBM). Galanis, E. , Anderson, S. K. , Lafky, J. M. , Kaufmann, T. J. ... - - Neuro-oncology - 2011 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776
Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial Galanis, E. , Anderson, S. K. , Lafky, J. M. , Uhm, J. , Giannini, C. ... - - Clin. Cancer Res. - 2013 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776
N047B: NCCTG phase II trial of vorinostat (suberoylanilide hydroxamic acid) in recurrent glioblastoma multiforme (GBM) Galanis, E. , Jaeckle, K. A. , Maurer, M. J. , Reid, J. M. ... - - J. Clin. Oncol. - 2007 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N047B
NCCTG phase II trial of bevacizumab in combination with sorafenib in recurrent GBM. Galanis, E. , Jaeckle, K. , Anderson, S. , Kaufmann, T. , Uhm, J. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0776
Vorinostat in glioblastoma multiforme (Gbm): updated results from phase I and II trials provide the rationale for further clinical development. Galanis, E. , Jaeckle, K. , Buckner, J. , Maurer, M. , Hardwick, J. ... - - Ann. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N047B
Phase I/II trial of vorinostat combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (N0874-ABTC0902, Alliance): Final results of the phase I trial Galanis, E. , Sarkaria, J. , Anderson, K. , Wu, W. , Jaeckle, K. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874
Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02 Galanis, Evanthia , Anderson, S Keith , Miller, C Ryan ... - - Neuro-oncology - 2018 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874
NCCTG N0872 (Alliance): A Randomized Placebo-Controlled Phase II Trial of Bevacizumab Plus Dasatinib in Patients with Recurrent Glioblastoma (GBM) Galanis, Evanthia , Anderson, S. Keith , Anastasiadis, Panagiotis Z. ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872
NCCTG N1174: Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naïve Patients with Recurrent Glioblastoma Multiforme (Alliance) Galanis, Evanthia , Anderson, S. Keith , Butowski, Nicholas ... - ASCO - J. Clin. Oncol. - 2017 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N1174
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902) Galanis, Evanthia , Anderson, S. Keith , Miller, C. Ryan ... - ASCO - J. Clin. Oncol. - 2014 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0874
A Phase I and Randomized Placebo-Controlled Phase II Trial of Bevacizumab plus Dasatinib in Patients with Recurrent Glioblastoma (GBM): Alliance/NCCTG N0872 Galanis, Evanthia , Anderson, S. Keith , Twohy, Erin L. ... - - Cancer - 2019 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0872
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study Galanis, Evanthia , Jaeckle, Kurt A. , Maurer, Matthew J. ... - - J Clin Oncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N047B
Central Pathology Review by Whole Slide Imaging in Glioblastoma Clinical Trials Giannini, Caterina , Miller, Ryan , Ligon, Keith , Tollefson, Helen ... - AANP - J Neuropathol Expl Neurol - 2015 Abstract - Secondary-not-in-original Endpoint - Meta-Analysis Analysis - Neuro-Onc - N0872 , N0877
New validated prognostic models and prognostic calculators in patients with low-grade gliomas diagnosed by central pathology review: a pooled analysis of EORTC/RTOG/NCCTG phase III clinical trials Gorlia, Thierry , Wu, Wenting , Wang, Meihua , Baumert, Brigitta G. ... - - Neuro-oncology - 2013 Manuscript - Secondary Endpoint - Comprehensive Analysis - Neuro-Onc - NCCTG-86-72-51
NCCTG N0272: phase II trial of imatinib mesylate; (gleevec; sti571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma: a north central cancer treatment group study. Jaeckle, K. A. , Anderson, S. K. , Kosel, M. , Sarkaria, J. ... - SNO - Neuro-oncology - 2011 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0272
NCCTG N0572 phase I/II trial of sorafenib and temsirolimus in patients with recurrent glioblastoma: A North Central Cancer Treatment Group study Jaeckle, K. A. , Schiff, D. , Anderson, S. K. , Galanis, E. ... - ASCO - J. Clin. Oncol. - 2011 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572
Correlation of response with survival endpoints in patients with newly diagnosed and recurrent glioblastoma (GBM) treated on prospective North Central Cancer Treatment Group (NCCTG) clinical trials Jaeckle, K. A. , Wu, W. , Kosel, M. , Flynn, P. J. ... - - J. Clin. Oncol. - 2008 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N047D
Phase I/II trial of sorafenib and CCI-779 in patients with recurrent glioblastoma (GBM) Jaeckle, K. , Anderson, K. , Sarkaria, J. , Decker, P. , Buckner, J. ... - ICTT - - 2008 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - NCCTG-N0572
Results of a phase II trial of vorinostat in patients with recurrent glioblastoma: Evidence of post-treatment histone acetylation in tumor tissue and pharmacokinetic analysis: North Central Cancer Treatment Group (NCCTG) study N047B Jaeckle, K. , Maurer, M. , Reid, J. , Ames, M. , Giannini, C. ... - TAT - - 2007 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N047B
NCCTG (Alliance) N0572: A phase II trial of sorafenib and temsirolimus in recurrent glioblastoma (GBM) patients who progress following prior RT/temozolomide (TMZ) and VEGF inhibitors (VEGFi) Jaeckle, K. , Schiff, D. , Anderson, S. , Galanis, E. , Stella, P. ... - ASCO - J. Clin. Oncol. - 2013 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0572
Phase I-II trial of imatinib mesylate (Gleevec; STI571) in treatment of recurrent oligodendroglioma and mixed oligoastrocytoma. North Central Cancer Treatment Group study N0272 (Alliance/NCCTG) Jaeckle, Kurt A. , Anderson, S K. , Twohy, Erin L. , Dixon, Jesse G. ... - - J. Neurooncol. - 2019 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0272
Correlation of enzyme-inducing anticonvulsant use with outcome of patients with glioblastoma Jaeckle, Kurt A. , Ballman, Karla , Furth, Alfred ... - - Neurology - 2009 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0475
CODEL (Alliance-N0577; EORTC-26081/22086; NRG-1071; NCIC-CEC-2): Phase III randomized study of RT vs. RT+TMZ vs. TMZ for newly diagnosed 1p/19q-codeleted anaplastic glioma. Analysis of patients treated on the original protocol design Jaeckle, Kurt , Vogelbaum, Michael , Ballman, Karla ... - AAN - Neurology - 2016 Abstract - Primary Endpoint - Comprehensive Analysis - Neuro-Onc - N0577
CODEL (Alliance N0577; EORTC 26081/22086 ; NRG 1071; NCIC CEC-2): A Phase III Randomized Intergroup Study for patients (pts) with newly diagnosed 1p/19q codeleted anaplastic glioma. Preliminary analysis of patients treated on the original protocol design with RT vs. RT + concomitant/adjuvant TMZ vs. TMZ alone Jaeckle, Kurt , Voglebaum, Michael , Ballman, Karla ... - SNO - Neuro Oncol - 2015 Abstract - Primary Endpoint - Comprehensive Analysis - Neuro-Onc - N0577
Improved outcome in recurrent glioblastoma (RGBM) patients treated with bevacizumab (BEV) and sorafenib (SOR) is predicted by a greater drop in apparent diffusion coefficient (ADC) on MRI imaging. Kaufmann, T. J. , Anderson, S. K. , Jaeckle, K. A. , Uhm, J. H. ... - SNO - 16th Annual Scientific Meeting of the Society for Neuro-Oncology in Conjunction with the AANS/CNS Section on Tumors - 2011 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - N0776
Phase I randomized phase II trial of either dasatinib or placebo combined with standard chemoradiotherapy for newly diagnosed glioblastoma multiforme (GBM): Final results of phase I study Laack, N. N. , Galanis, E. , Leinweber, C. , Buckner, J. C. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0877
Randomized Placebo-Controlled Phase II Study of Dasatinib with Standard Chemo-Radiotherapy for Newly Diagnosed Glioblastoma (GBM), N0877 Laack, Nadia , Galanis, Eva , Anderson, S. Keith , Leinweber, Clinton ... - ASCO - J. Clin. Oncol. - 2015 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N0877
Joint NABTC + NCCTG prognostic factors analysis for high grade recurrent glioma Lamborn, K. , Wu, W. , Prados, M. , Jaeckle, K. , Chang, S. ... - - J. Clin. Oncol. - 2007 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - N0678
Validation of Single-Item Linear Analog Scale Assessment of Quality of Life in Neuro-Oncology Patients Locke, Dona E.C. , Decker, Paul A. , Sloan, Jeff A. , Brown, Paul D. ... - - J Pain Symptom Manage - 2007 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - N0074 , NCCTG-98-72-51 , NCCTG-98-72-52
NCCTG N057K phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: A North Central Cancer Treatment Group trial. Ma, D. , Galanis, E. , Schiff, D. , Wu, W. , Peller, P. J. ... - - J. Clin. Oncol. - 2012 Abstract - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - N057K
A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K Ma, Daniel J. , Galanis, Evanthia , Anderson, S. Keith ... - - Neuro-oncology - 2015 Manuscript - Primary Endpoint - Long-Term-Followup Analysis - Neuro-Onc - N057K
N107C/CEC.3 (Alliance for Clinical Trials in Oncology/Canadian Cancer Trials Group): Phase III Trial of Post-Operative Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease: Cognitive function of long-term survivors Roberge, David , Ballman, Karla V. , Cerhan, Jane H. ... - SNO - Neuro-Oncology - 2017 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - N107C
Phase II trial of two different irinotecan schedules with pharmacokinetic analysis in patients with recurrent glioma: North Central Cancer Treatment Group results Santisteban, Marta , Buckner, Jan C. , Reid, Joel M. , Wu, Wenting ... - - J Neurooncol - 2009 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-96-72-51
NCCTG phase I trial of Everolimus (RAD001) and Temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients (N057K). Sarkaria, J. N. , Galanis, E. , Peller, P. J. , Brown, P. D. , Wu, W. ... - - Mol Cancer Ther - 2009 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N057K
NCCTG phase I trial of temsirolimus (CCI-779) and temozolomide (TMZ) in combination with radiation therapy (RT) in newly diagnosed glioblastoma multiforme (GBM) patients Sarkaria, J. N. , Galanis, E. , Wu, W. , Giannini, C. , Jaeckle, K. A. ... - - J. Clin. Oncol. - 2009 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - N027D
Effect of combined therapy with temsirolimus (CCI-779), temozolomide (TMZ), and radiation (RT) in newly diagnosed glioblastoma multiforme (GBM) patients on immune suppression: results from NCCTG N027D Sarkaria, J. , Galanis, E. , Gustafson, M. , Dietz, A. , Wu, W. ... - - J. Clin. Oncol. - 2010 Abstract - Primary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N027D
FLT-PET analysis of early response to everolimus in newly diagnosed glioblastoma patients enrolled on NCCTG N057K Sarkaria, J. , Peller, P. , Galanis, E. , Jacobson, M. , Wu, W. ... - - J. Clin. Oncol. - 2011 Abstract - Secondary Endpoint - Primary Analysis - Neuro-Onc - NCCTG-N057K
Combination of temsirolimus (CCI-779) with chemo-radiation in newly diagnosed GBM (NCCTG trial N027D) is associated with increased infectious risks1 Sarkaria, Jann N. , Galanis, Eva , Wu, Wenting , Dietz, Allan B. ... - - Clin Cancer Res - 2010 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N027D
NCCTG Phase I Trial N057K of Everolimus (RAD001) and Temozolomide in Combination with Radiation Therapy in Newly Diagnosed Glioblastoma Multiforme Patients1 Sarkaria, Jann N. , Galanis, Evanthia , Wu, Wenting ... - - Int J Radiat Oncol Biol Phys - 2011 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N057K
Phase I study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North central cancer treatment group (NCCTG) N0572 Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2007 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572
Feasibility/tolerability results from a phase I/II study of temsirolimus (CCI-779) and sorafenib in recurrent glioblastoma: North Central Cancer Treatment Group (NCCTG) N0572 Schiff, D. , Sarkaria, J. , Decker, P. , Buckner, J. , Galanis, E. ... - SNO - Neuro-oncology - 2009 Abstract - Primary Endpoint - Preliminary Analysis - Neuro-Onc - N0572
Phase I/II Trial of Temsirolimus and Sorafenib in Treatment of Patients with Recurrent Glioblastoma: North Central Cancer Treatment Group Study/Alliance N0572 Schiff, David , Jaeckle, Kurt A , Anderson, S. Keith ... - - Cancer - 2018 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0572
Brain Metastases From Melanoma Schild, Steven E. , Behl, Deepti , Markovic, Svetomir N. ... - - Am. J. Clin. Oncol. - 2010 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0274
Optimizing whole brain radiotherapy dose and fractionation: Results from a prospective phase III trial (Alliance) Trifiletti, Daniel M. , Ballman, Karla V. , Brown, Paul D. ... - ASTRO - International Journal of Radiation Oncology • Biology • Physics - 2019 Abstract - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - N107C
Optimizing Whole Brain Radiation Therapy Dose and Fractionation: Results From a Prospective Phase 3 Trial (NCCTG N107C [Alliance]/CEC.3). Trifiletti, Daniel M , Ballman, Karla V , Brown, Paul D ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2020 Manuscript - Secondary-not-in-original Endpoint - Primary Analysis - Neuro-Onc - N107C
Phase II evaluation of gefitinib in patients with newly diagnosed grade 4 astrocytoma: Mayo/North Central Cancer Treatment Group study N0074 1 Uhm, Joon H. , Ballman, Karla V. , Wu, Wenting , Giannini, Caterina ... - - Int. J. Radiat. Oncol. Biol. Phys. - 2011 Manuscript - Primary Endpoint - Primary Analysis - Neuro-Onc - N0074
Relationship between overall survival and progression-free survival for recent NCCTG glioblastoma multiforme trials Wu, W. , Galanis, E. , Buckner, J. C. , Jaeckle, K. A. ... - ASCO - J. Clin. Oncol. - 2012 Abstract - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - Comprehensive
Joint NCCTG and NABTC prognostic factors analysis for high-grade recurrent glioma Wu, Wenting , Lamborn, Kathleen R. , Buckner, Jan C. ... - - Neuro Oncol - 2010 Manuscript - Secondary-not-in-original Endpoint - Comprehensive Analysis - Neuro-Onc - N0678
